科研之友
微信
新浪微博
Facebook
分享链接
摘要
Teplizumab and otelixizumab are non-FcR-binding anti-CD3 monoclonal antibodies (mAbs) that have been tested in early clinical trials for the treatment of recent-onset type 1 diabetes. They act to arrest the autoimmune destruction of pancreatic islet beta-cells, which leads to the preservation of endogenous insulin production. Clinical trials of teplizumab and otelixizumab are ongoing to investigate their use for maintaining insulin responses. It is hoped that in the future non-FcR-binding anti-CD3 mAbs may be used as single agents or in combination with other immunomodulating therapies with insulin at the onset of hyperglycemia to improve clinical outcomes.
- 出版日期2010-10
